Quantcast

Latest Organic chemistry Stories

2014-05-20 23:14:29

On May 15, the FDA warned that Eszopiclone Containing Sleep Aids (including Lunesta and generics) can cause next-day impairment of driving and other activities that require alertness. In light of this news, AttorneyOne, a recognized authority on law, updated the website providing detailed information to consumers. San Diego, CA (PRWEB) May 20, 2014 AttorneyOne.com, a recognized authority on law, update the website daily regarding all the latest information from the FDA on safety alerts...

2014-05-20 23:02:55

New comprehensive research report “Ovarian Cancer Therapeutics in Major Developed Markets to 2020 - Late-Stage Pipeline Focuses on Improved Progression Free-Surival and Targeted Therapies” elaborated by GBI Research is now available at MarketPublishers.com. According to the study, the global ovarian cancer therapeutics market is anticipated to post a 3.4% CAGR through 2020. London, UK (PRWEB) May 20, 2014 At present, the overall ovarian cancer therapeutics market is led by the use of...

2014-05-20 12:33:19

Oncoprex Combined with Tarceva for Patients With and Without EGFR Mutations AUSTIN, Texas, May 20, 2014 /PRNewswire/ -- Genprex, Inc. announced today that it has enrolled the first patient in a clinical trial evaluating its lead product candidate Oncoprex® in combination with erlotinib (Tarceva®) for late-stage lung cancer patients. Oncoprex is a targeted biologic incorporating the pan-kinase inhibitor TUSC2, which inhibits oncogenic kinases via multiple pathways. The trial is...

2014-05-20 08:34:22

AADi Initiates NIH Funded Clinical Trial for Patients with Bladder Cancer PACIFIC PALISADES, Calif., May 20, 2014 /PRNewswire/ -- AADi, LLC, a clinical stage biopharmaceutical company focused on treating diseases uniquely suited for nanotechnology approaches, today announced the inlicensing of ABI-009 from Celgene Corporation (NASDAQ:CELG). ABI-009 is the nanoparticle albumin-bound (nab®) version of the mTOR inhibitor sirolimus or rapamycin and leverages the same technology of the...

2014-05-20 08:32:11

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, May 20, 2014 /PRNewswire/ -- Today, Analysts Review released its analysts' notes regarding Gilead Sciences, Inc. (NASDAQ: GILD), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Puma Biotechnology, Inc. (NYSE: PBYI). Private wealth members receive these notes ahead of publication. To reserve...

2014-05-20 08:31:56

NASDAQ: CRME TSX: COM VANCOUVER, May 20, 2014 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME) (TSX: COM) today announced an agreement with AOP Orphan Pharmaceuticals AG, headquartered in Vienna, Austria, to commercialize AGGRASTAT(®) (tirofiban HCl) in selected European markets. AOP Orphan will be responsible for the commercialization of AGGRASTAT in the AOP Orphan countries. Under terms of the agreement, AOP Orphan has agreed to specific annual commercial goals for...

2014-05-19 23:12:15

There is “an increased frequency of latent EBV-infected B cells in MS,” according to a study published in Acta Neurologica Scandinavica on March 31, 2014 (1). polyDNA reviews the study and recommends that patients with MS talk to their doctors about Gene-Eden-VIR and Novirin. Rochester, NY (PRWEB) May 19, 2014 Epstein-Barr virus (EBV) infection is associated with multiple sclerosis (MS). One recent study found that “Patients with multiple sclerosis (MS) have elevated antibodies...

2014-05-19 16:24:31

CHICAGO, May 19, 2014 /PRNewswire/ -- Ajinomoto North America, Inc. announced today that Advantame, an innovative new sweetener, has successfully completed the food additive petition process for general use in foods and beverages according to the U.S. Food and Drug Administration (FDA). http://photos.prnewswire.com/prnvar/20140519/89031 Advantame has a sweet, clean sugar-like taste. Because it is much sweeter than most low and non-calorie sweeteners currently available, it is...

2014-05-19 12:42:01

Henry Ford Health System A vast majority of so-called "super-frequent user" patients who seek care in the Emergency Department (ED) have a substance abuse addiction, according to a Henry Ford Hospital study. A patient is considered a super-frequent user who visits the ED at least 10 times a year. ED physicians have long theorized that patients who frequent the ED for their care have a substance abuse addiction. Few studies have actually measured the rate of addiction of these...

2014-05-19 12:34:04

European Society of Cardiology Serelaxin has neutral effect on diuretic response Poor diuretic response is associated with worse in-hospital and post-discharge clinical outcomes, results of the RELAX-AHF trial reveal. The study also found that serelaxin has a neutral effect on diuretic response. These novel data from the RELAX-AHF trial were presented by lead author Professor Adriaan A. Voors at the Heart Failure Congress 2014, held 17-20 May in Athens, Greece. The Congress is the...


Latest Organic chemistry Reference Libraries

Organometallics
2012-05-17 15:18:17

Organometallics is a peer-reviewed scientific journal published by the American Chemical Society. As of May 2012, the editor-in-chief is John A. Gladysz. Organometallics publishes records in one of the most active fields for organometallic, inorganic, organic, and materials chemists. Articles, communications, mini-reviews, and notes detail the synthesis, structure, bonding, chemical reactivity and reaction mechanisms, and applications of organometallic and organometalloidal compounds....

Synthetic Metals
2012-05-17 14:54:38

Synthetic Metals is a peer-reviewed scientific journal published by Elsevier. It covers all aspects of electronic polymers and electronic molecular materials. It is an international medium for the rapid publication of original research papers, short communications and subject reviews dealing with research on and applications of electronic polymers and electronic molecular materials including novel carbon architectures. Original manuscripts on chemical, electrochemical, electrical, photonic...

More Articles (2 articles) »
Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.